secwatch.observer — SEC 8-K summary
======================================

Issuer:     C4 Therapeutics, Inc. (CCCC)
CIK:        0001662579
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001628280-25-049850
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

C4 Therapeutics reports Q3 net loss $32.2M, raises $125M; cemsidomide 53% ORR at 100 µg
--------------------------------------------------------------------------------

- Revenue $11.2M, net loss $32.2M ($0.44 EPS) vs $15.4M revenue and $24.7M loss in Q3 2024.
- Completed equity offering of $125M gross proceeds in Oct 2025; potential additional $225M from warrants.
- Phase 1 cemsidomide data: 53% ORR at 100 µg dose; one patient achieved MRD-negative complete response.
- Entered clinical trial collaboration with Pfizer to evaluate cemsidomide + elranatamab; Pfizer supplies drug at no cost.
- Cash $199.8M as of Sep 30, excluding $125M raise; runway extended to end of 2028.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1662579/000162828025049850/0001628280-25-049850-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1662579/000162828025049850/cccc-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001628280-25-049850

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer